BASEL

Marmy Rank SEO-Consulting Launches New Website to Provide Customized SEO Solutions to Businesses Worldwide

Retrieved on: 
Friday, February 24, 2023
Learning, Blog, Research, SEO, Forte dei Marmi, Consultant, Sales, Online shopping

With its newly launched website Marmy Rank is perfectly positioned to help clients improve online visibility and increase website traffic through effective SEO strategies.

Key Points: 
  • With its newly launched website Marmy Rank is perfectly positioned to help clients improve online visibility and increase website traffic through effective SEO strategies.
  • Businesses seeking consulting for SEO Basel and SEO Beratung can’t compete with, look no further than Marmy Rank SEO-Consulting.
  • Proper and effective SEO can help grow a company’s online presence organically, which helps the website rank higher in search engines.
  • The new Marmy Rank SEO-Consulting website is a testament to the company’s commitment to provide customized and expert SEO solutions to clients.

Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update

Retrieved on: 
Tuesday, February 21, 2023
MBA, Vaccine, SARS-CoV-2, Therapy, Projection, Safety, COVID-19, Patient, Incidence, Swiss Federal Nuclear Safety Inspectorate, Public health, Public, Infection, KNRS, Pharmaceutical industry

Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, provided an update today on progress of its Phase 2 KINFAST trial of KIN001 in Covid-19.

Key Points: 
  • Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, provided an update today on progress of its Phase 2 KINFAST trial of KIN001 in Covid-19.
  • “We’re pleased with the progress of KINFAST to date,” said Thierry Fumeaux M.D.
  • MBA, Chief Medical Officer of Kinarus Therapeutics, and former Chairman of the Covid-19 task force of the Swiss Federal Office of Public Health.
  • Notably, no safety concerns associated with KIN001 have been identified among the patients who have completed the two-week treatment regimen.

ARTIDIS Announces Appointment of Dr. Ajit Singh, Ph.D. to Board of Directors

Retrieved on: 
Monday, February 13, 2023
USD, Stanford School, Health, Diagnosis, Partnership, Growth, Cancer, Ajit, University, Stanford University School of Medicine, MD Anderson Cancer Center, Patient, Silicon, Management

ARTIDIS Announces Appointment of Dr. Ajit Singh, Ph.D. to Board of Directors

Key Points: 
  • ARTIDIS Announces Appointment of Dr. Ajit Singh, Ph.D. to Board of Directors
    Basel, Switzerland, February 13, 2023 – ARTIDIS AG, a clinical stage medical technology company on a mission to shift the paradigm of cancer care from central lab to patient bedside, today announced the appointment of Dr. Ajit Singh, Ph.D., to the ARTIDIS Board of Directors, effective February 9, 2023.
  • As a member of the ARTIDIS Board of Directors, Dr. Singh, Ph.D., will provide pivotal support to ARTIDIS as the company is approaching the commercialization phase.
  • He will add a range of new expertise and experience to the ARTIDIS board.
  • I consider it a privilege to be a part of the ARTIDIS journey - onward and upward,” said Dr. Singh, Ph.D.
    “I am thrilled to have Ajit join the ARTIDIS Board.

Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma

Retrieved on: 
Thursday, February 2, 2023
Molar, NK, Safety, Patient, MD, Immunotherapy, Pharmaceutical industry

BASEL, Switzerland, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the first patient has been dosed in the OMNIA-1 study – a Phase I/II study assessing the efficacy and safety of ANV419 for the treatment of advanced melanoma.

Key Points: 
  • BASEL, Switzerland, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the first patient has been dosed in the OMNIA-1 study – a Phase I/II study assessing the efficacy and safety of ANV419 for the treatment of advanced melanoma.
  • ANV419 is a powerful, IL-2Rbeta selective IL-2 agonist, which has been specifically designed to enable the delivery of high dose IL-2.
  • Despite substantial progress, 30% to 70% of patients do not respond to initial anti-programmed death 1/ligand 1 (PD-1/L1) therapy, and approximately 25% eventually progress.
  • Thus, the overall outlook for patients with metastatic cutaneous melanoma remains challenging and the development of new effective and tolerable therapy is needed¹.

SmartWork: Putting Users at the Centre with Adaptive and Flexible Working Solutions for Businesses and Daily Life

Retrieved on: 
Monday, January 16, 2023
Smart Work, Agility, Social media, Job, Communication, Employment agency, Online shopping, Candidate

Summary: SmartWork has emerged as an innovative job-matching platform. Recently, the company has introduced new services to improve the recruitment process.

Key Points: 
  • According to the founder, Andrea Vögeli this innovative hiring platform is set to revolutionise how job seekers and employers connect.
  • Furthermore, SmartWork comes across as a comprehensive hiring platform that simplifies the job search process for both alike.
  • With its advanced search capabilities, job seekers can quickly and easily find jobs that match their skills, experience, and interests.
  • The platform also provides job seekers detailed information about each job, including job descriptions, requirements and benefits.

Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan

Retrieved on: 
Tuesday, January 17, 2023
Pulmonary fibrosis, Teaching hospital, COVID-19, End organ damage, Chemokine, University Hospital of Basel, Pathology, RNA-Seq, PD, Lung, Patient, Idiopathic pulmonary fibrosis, FVC, Transfusion-related acute lung injury, Probability, IPF, KNRS, Pharmaceutical industry, Pirfenidone, Muthiri kinaru

Kinarus Therapeutics AG (SIX:KNRS) “Kinarus”, a Swiss clinical-stage biopharmaceutical company announced today preclinical data supporting the potential effectiveness of its lead clinical candidate, KIN001, as an oral treatment for idiopathic pulmonary fibrosis (IPF).

Key Points: 
  • Kinarus Therapeutics AG (SIX:KNRS) “Kinarus”, a Swiss clinical-stage biopharmaceutical company announced today preclinical data supporting the potential effectiveness of its lead clinical candidate, KIN001, as an oral treatment for idiopathic pulmonary fibrosis (IPF).
  • In a mouse model of lung injury, KIN001 significantly reduced lung weights and tissue fibrosis score vs. controls.
  • The combination of KIN001 with pirfenidone demonstrated greater reduction in lung fibrosis, indicating the potential for additional benefit of KIN001 in combination with the current standard of care.
  • KIN001 significantly reduced the upregulation of multiple key inflammatory cytokines and chemokines implicated in the pathology of lung fibrosis.

UPDATE -- Noema Pharma to Attend and Present at 41st Annual J.P. Morgan Healthcare Conference in San Francisco

Retrieved on: 
Thursday, January 5, 2023
Conference, Incident management team, Senior management, CNS, Pharmaceutical industry, Fine chemical

BASEL, Switzerland and BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced that members of the Management Team will attend and present at the 41st Annual J.P. Morgan Healthcare Conference taking place on January 9-12, 2023 in San Francisco, CA.

Key Points: 
  • BASEL, Switzerland and BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced that members of the Management Team will attend and present at the 41st Annual J.P. Morgan Healthcare Conference taking place on January 9-12, 2023 in San Francisco, CA.

Noema Pharma to Attend and Present at 41st Annual J.P. Morgan Healthcare Conference in San Francisco

Retrieved on: 
Thursday, January 5, 2023
Conference, Incident management team, Senior management, CNS, Pharmaceutical industry, Fine chemical

BASEL, Switzerland and BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced that members of the Management Team will attend and present at the 41st Annual J.P. Morgan Healthcare Conference taking place on January 9-12, 2023 in San Francisco, CA.

Key Points: 
  • BASEL, Switzerland and BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced that members of the Management Team will attend and present at the 41st Annual J.P. Morgan Healthcare Conference taking place on January 9-12, 2023 in San Francisco, CA.

VectivBio Announces Results of Extraordinary General Meeting

Retrieved on: 
Friday, December 9, 2022
Extraordinary general meeting, Acquisition, Respiration (physiology), MMA, Congenital disorders of amino acid metabolism, Manufacturing execution system, Degenerative disease, Short bowel syndrome, Propionic acidemia, NAMS, Community of Metros, Coenzyme A, University of Groningen, Growth, General partnership, Business administration, Pantetheine, University, Novartis, International business, Patient, SBS, Fine chemical

BASEL, Switzerland, Dec. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Wouter Joustra was elected as a new member of the Board of Directors at the Extraordinary General Meeting held on December 9, 2022.

Key Points: 
  • BASEL, Switzerland, Dec. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Wouter Joustra was elected as a new member of the Board of Directors at the Extraordinary General Meeting held on December 9, 2022.
  • Mr. Wouter Joustra brings a breadth of capital markets and investment experience in the life sciences investment industry to VectivBio.
  • He joined Forbion, a leading European life sciences venture capital firm, in October 2019, where he is currently General Partner.
  • His deep experience in life-science capital markets will benefit VectivBio as we enter our next stage of growth,” said Tom Woiwode, VectivBio Board Chairman.

Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5

Retrieved on: 
Tuesday, December 6, 2022
Roche, Virology, Patient, AMD, Inflammation, Membrane protein, Antibody, Omicron, Probability, IPF, Doctor of Philosophy, Pioglitazone, Vaccine, COVID-19, Infection, Research, MAPK, Severe acute respiratory syndrome coronavirus 2, KNRS, Therapy, Pharmaceutical industry, Muthiri kinaru

Basel, Switzerland, 6 December 2022 -- Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announced new preclinical data showing KIN001’s strong antiviral efficacy against the SARS-CoV-2 Omicron subvariants BA.2 and BA.5.

Key Points: 
  • Nevertheless, it is highly encouraging that KIN001 has demonstrated equivalent activity against the SARS-CoV-2 Omicron BA.2 and BA.5 subvariants.” said Alexander Bausch, PhD, CEO of Kinarus.
  • KIN001 may fight Covid-19 in three ways: anti-viral activity may prevent viral replication; anti-inflammatory activity may reduce excessive inflammation (e.g.
  • Since pioglitazone enhances the durability and antiviral effects of pamapimod, KIN001 may be a more effective treatment than single agents targeting only p38 MAPK.
  • Kinarus possesses the exclusive worldwide license to the molecule and has developed KIN001, a combination with pioglitazone.